Cite
HARVARD Citation
Heidenreich, R. et al. (n.d.). RNAdjuvant®, a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile. Journal for immunotherapy of cancer. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Heidenreich, R. et al. (n.d.). RNAdjuvant®, a novel, highly-potent RNA-based adjuvant, combines strong immunostimulatory capacities with a favorable safety profile. Journal for immunotherapy of cancer. p. . [Online].